It's silly cheap.
As Dr Maiti said, "We should find out pretty early on." It's all about pushing those deep remissions back. His goal is to increase overall survival rate by 10-15%, " but if the trials follow the clinical data it could be much much higher. "
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-6
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $17.98M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $28.15K | 1.320M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 938219 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 116461 | 2 |
View Market Depth
| Last trade - 15.50pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
-0.001 ( 2.22 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.2¢ | 2.1¢ | 798132 | ||
| Last updated 14.32pm 17/05/2024 ? | |||||
| CHM (ASX) Chart |